摘要
尽管化学免疫治疗的出现代表了显著的治疗方式的进展,传统方式仍然无法治愈慢性淋巴细胞白血病(CLL)。被定义为在治疗的6个月内无反应或复发的难治性CLL,会引起多种预后因素,如p53通路中断,病情恶化,严重感染的风险增加,治疗反应不佳,这都会导致总生存期很短。因此,难治性CLL对于血液学家和患者来说是极具挑战性的情形。因为临床试验将复发和难治性病人混合在一起,所以难治性白血病数据的数量和质量都是相当有限的。难治性白血病的治疗方案有阿仑单抗,Ofatumumab,以氟达拉滨和苯达莫司汀为基础的方案,以铂类为基础的有效方案和高剂量糖皮质激素联合单克隆抗体。Ibrutinib和idelalisib的近期发现,(利用)小分子干扰B细胞受体通路,革新了难治性白血病治疗的长期新概念,口服疗法开始变得速效和提升总生存。异基因造血干细胞移植仍然被认为是唯一的治疗潜力选择。这篇综述审查的重点是治疗难治性白血病目前可用的策略。
关键词: 慢性淋巴细胞性白血病难治,ibrutinib,idelalisib,利妥昔单抗,Ofatumumab,异基因造血干细胞移植。
图形摘要
Current Cancer Drug Targets
Title:Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge
Volume: 16 Issue: 8
Author(s): Lukas Smolej
Affiliation:
关键词: 慢性淋巴细胞性白血病难治,ibrutinib,idelalisib,利妥昔单抗,Ofatumumab,异基因造血干细胞移植。
摘要: Despite impressive therapeutic progress represented by the advent of chemoimmunotherapy, chronic lymphocytic leukemia (CLL) remains incurable by conventional modalities. Refractory CLL defined by non-response to treatment or relapse/progression within 6 months is associated with multiple unfavourable prognostic factors such as p53 pathway disruption, deteriorating patient condition, increased risk of severe infections, and poor response to treatment, resulting in a very short overall survival. Therefore, refractory CLL represents a highly challenging situation for the hematologist as well as the patient. The amount and quality of data on refractory CLL are rather limited as clinical trials usually combine patients with relapsed and refractory disease. Therapeutic options for refractory CLL include alemtuzumab, ofatumumab, fludarabine- and bendamustine-based regimens, platinum-based aggressive protocols and high-dose corticosteroids combined with monoclonal antibodies. The recent introduction of ibrutinib and idelalisib, small molecules interfering with B-cell receptor pathways, revolutionized the treatment of refractory CLL by the novel concept of long-term, oral treatment leading to impressive progression-free and overall survival improvement. Allogeneic stem cell transplantation is still considered the only option with curative potential. This review focuses on the currently available therapeutic strategies for refractory CLL.
Export Options
About this article
Cite this article as:
Lukas Smolej , Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge, Current Cancer Drug Targets 2016; 16 (8) . https://dx.doi.org/10.2174/1568009616666160408150032
DOI https://dx.doi.org/10.2174/1568009616666160408150032 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Recent Developments in the Synthesis and Biological Activity of Muramylpeptides
Current Medicinal Chemistry Polysaccharide Colloids as Smart Vehicles in Cancer Therapy
Current Pharmaceutical Design High-Dose Linoleic Acid Activated JAK2-STAT3 Signaling Pathway Involved in Cytokine Production and Lipogenesis in Pancreatic Exocrine Cells
Current Molecular Medicine Pharmacophore Modelling as a Virtual Screening Tool for the Discovery of Small Molecule Protein-protein Interaction Inhibitors
Current Pharmaceutical Design Recent Advances in Epitope Design for Immunotherapy of Cancer
Recent Patents on Anti-Cancer Drug Discovery Synthetic Peptides in the Diagnosis of HIV Infection
Current Protein & Peptide Science BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Editorial [ Hot Topic: Highlights on Important Signaling Pathways as Drug Targets in Hematological Malignancies (Guest Editors: H. Serve and H.C. Hasselbalch) ]
Current Drug Targets Cationicity and Hydrophobicity Enhance the Cytotoxic Potency of Phoratoxin C Anticancer Peptide Analogues against Triple Negative Breast Cancer Cells
Current Bioactive Compounds Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds The Stable Isotope Use in the Exploration of Bioavailability and Metabolism of Magnesium
Current Nutrition & Food Science Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry Editorial (Hot Topic Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the Treatment of Cancer)
Current Cancer Drug Targets General Principles for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia
Current Drug Targets Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics